Asterias Biotherapeutics A Global Leader In Regenerative Medicine Home Company About Asterias Executive Management Board of Directors The Asterias Name Investors Events & Presentations Corporate Governance SEC Filings News Releases Disclaimer/Forward Looking Statements Platforms Pluripotent Stem Cells Immunotherapy Supporting Information Intellectual Property Scientific Publications Scientific Presentations Pipeline AST-OPC1 AST-VAC1 AST-VAC2 Contact Cell Therapy for Unmet Medical Needs Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. Our industry leading platforms are based on pluripotent stem cells and allogeneic immunotherapy. Current programs focus on spinal cord injury and cancer. We are traded on the NYSE MKT under the ticker symbol AST. Clinical Trials Spinal Cord Injury Research Study Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with complete cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 14 and 30 days after injury. Researchers will also assess the impact on patient hand and arm function. Learn More Latest News Asterias Biotherapeutics Announces Publication of Preclinical Data that Supports the Safety and Use of AST-OPC1 as a Treatment for Spinal Cord Injury (SCI) Date: Sep 09, 2015 Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury Date: Aug 31, 2015 More News Investors Stock Quote AST Investor Presentations Sep 10, 2015 Asterias Biotherapeutics to Present at the 4th Annual Gateway Investor Conference To view the webcast please click here View More Asterias Biotherapeutics Tel: (650) 433-2900 Investor Relations InvestorRelations@asteriasbio.com (650) 433-2992 Media Relations News@asteriasbio.com About Asterias Trials Contact Home Company About Asterias Executive Management Board of Directors The Asterias Name Investors Events & Presentations Corporate Governance SEC Filings News Releases Disclaimer/Forward Looking Statements Platforms Pluripotent Stem Cells Immunotherapy Supporting Information Intellectual Property Scientific Publications Scientific Presentations Pipeline AST-OPC1 AST-VAC1 AST-VAC2 Contact